

Rapid Recommendations

PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations

Qiukui Hao, methods co-chair, geriatrician 1 2 3,

Bert Aertgeerts, chair, general practitioner, methodologist 4,

Gordon Guyatt, general internist, methodologist 3,

Geertruida E Bekkering, patient partnership liaison, methodologist 4,

Per Olav Vandvik, general internist, methodologist 5 6,

Safi U Khan, cardiologist 7,

Nicolas Rodondi, general internist, methodologist 8 9,

Rod Jackson, epidemiologist 10,

Jean-Luc Reny, general internist 11 12,

Lubna Al Ansary, general practitioner 13,

Mieke Van Driel, general practitioner 14,

Willem J J Assendelft, general practitioner 15,

Thomas Agoritsas, general internist, methodologist 16,

Frederick Spencer, cardiologist 17,

Reed A C Siemieniuk, general internist, methodologist 3 17,

Lyubov Lytvyn, patient partnership liaison, methodologist 3 6,

Anja Fog Heen, general internist, methodologist 18,

Qian Zhao, general practitioner 19,

Irbaz Bin Riaz, medical doctor 20,

Dirk Ramaekers, general internist 21,

Patrick Mba Okwen, general practitioner 22,

Ye Zhu, cardiologist 23,
Annabel Dawson, patient partner 24,
Mersa Caius Ovidiu, patient partner 25,
Willy Vanbrabant, patient partner 26,
Sheyu Li, endocrinologist, methodologist 27 28,
Nicolas Delvaux, general practitioner, methodologist 4

1. The Center of Gerontology and Geriatrics/National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China
2. School of Rehabilitation Science, McMaster University, Hamilton, Ontario, Canada
3. Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada
4. Department of Public Health and Primary Care and MAGIC Primary Care, Academisch Centrum voor Huisartsgeneeskunde, KU Leuven, Belgium
5. Clinical Effectiveness Research Group, Institute of Health and Society, University of Oslo, Oslo, Norway
6. MAGIC Evidence Ecosystem Foundation
7. Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, Houston TX, USA
8. Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland
9. Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
10. School of Population Health, Faculty of Medical & Health Sciences, University of Auckland, New Zealand
11. General Internal Medicine, University Hospital of Geneva, Geneva, Switzerland
12. Faculty of Medicine, Geneva University, Switzerland
13. Department of Family and Community Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia
14. Primary Care Clinical Unit, Faculty of Medicine, University of Queensland, Brisbane, Australia
15. Department of Primary and Community Care, Radboud University Medical Center, Netherlands
16. Division General Internal Medicine & Division of Clinical Epidemiology, University Hospitals of Geneva, Geneva, Switzerland
17. Department of Medicine, McMaster University, Hamilton, ON, Canada

18. Department of Medicine, Lovisenberg Diaconal Hospital, Oslo, Norway
 19. International Medical Center / Ward of General Practice, West China Hospital, Sichuan University, Chengdu, China
 20. Department of Medicine, Hematology Oncology, Mayo Clinic, Arziona, USA
 21. KU Leuven Institute for Healthcare Policy, University of Leuven, Kapucijnenvoer 35, 3000 Leuven, Belgium.
 22. Effective Basic Services (eBase), Africa, Nkwen Bamenda, Cameroon
 23. Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China
 24. United Kingdom
 25. Romania
 26. UZ Leuven GHB, Belgium
 27. Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China
 28. Department of Guideline and Rapid Recommendation, Cochrane China Center, MAGIC China Center, Chinese Evidence-based Medicine Center, West China Hospital, Sichuan University, Chengdu, China
- Correspondence to: N Delvaux nicolas.delvaux@kuleuven.be, S Li lisheyu@gmail.com

Abstract

Clinical question In adults with low density lipoprotein (LDL) cholesterol levels >1.8 mmol/L (>70 mg/dL) who are already taking the maximum dose of statins or are intolerant to statins, should another lipid-lowering drug be added, either a proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor or ezetimibe, to reduce the risk of major cardiovascular events? If so, which drug is preferred? Having decided to use one, should we add the other lipid-lowering drug?

Current practice Most guidelines emphasise LDL cholesterol targets in their recommendations for prescribing PCSK9 inhibitors and/or ezetimibe in adults at high risk of experiencing a major adverse cardiovascular event. However, to achieve these goals in very high risk patients with statins alone is almost impossible, so physicians are increasingly considering other lipid-lowering drugs solely for achieving LDL cholesterol treatment goals rather than for achieving important absolute cardiovascular risk reduction. Most guidelines do not systematically assess the cardiovascular benefits of adding PCSK9 inhibitors and/or ezetimibe for all risk groups across primary and secondary prevention, nor do they report, in accordance with explicit judgments of assumed patients' values and preferences, absolute benefits and harms and potential treatment burdens.

Recommendations The guideline panel provided mostly weak recommendations, which means we rely on shared decision making when applying these recommendations. For adults already using statins, the panel suggests adding a second lipid-lowering drug in people at very high and high cardiovascular risk but recommends against adding it in people at low cardiovascular risk. For adults who are intolerant to statins, the panel recommends using a lipid-lowering drug in people at very high and high cardiovascular risk but against adding it in those at low cardiovascular risk. When choosing to add another lipid-lowering drug, the panel suggests ezetimibe in preference to PCSK9 inhibitors. The panel suggests further adding a PCSK9 inhibitor to ezetimibe for adults already taking statins at very high risk and those at very high and high risk who are intolerant to statins.

How this guideline was created An international panel including patients, clinicians, and methodologists produced these recommendations following standards for trustworthy guidelines and using the GRADE approach. The panel identified four risk groups of patients (low, moderate, high, and very high cardiovascular risk) and primarily applied an individual patient perspective in moving from evidence to recommendations, though societal issues were a secondary consideration. The panel considered the balance of benefits and harms and burdens of starting a PCSK9 inhibitor and/or ezetimibe, making assumptions of adults' average values and preferences. Interactive evidence summaries and decision aids accompany multi-layered recommendations, developed in an online authoring and publication platform (www.magicapp.org) that also allows re-use and adaptation.

The evidence A linked systematic review and network meta-analysis (14 trials including 83 660 participants) of benefits found that PCSK9 inhibitors or ezetimibe probably reduce myocardial infarctions and stroke in patients with very high and high cardiovascular risk, with no impact on mortality (moderate to high certainty evidence), but not in those with moderate and low cardiovascular risk. PCSK9 inhibitors may have similar effects to ezetimibe on reducing non-fatal myocardial infarction or stroke (low certainty evidence). These relative benefits were consistent, but their absolute magnitude varied based on cardiovascular risk in individual patients (for example, for 1000 people treated with PCSK9 inhibitors in addition to statins over five years, benefits ranged from 2 fewer strokes in the lowest risk to 21 fewer in the highest risk). Two systematic reviews on harms found no important adverse events for these drugs (moderate to high certainty evidence). PCSK9 inhibitors require injections that sometimes result in injection site reactions (best estimate 15 more per 1000 in a 5 year timeframe), representing a burden and harm that may matter to patients. The MATCH-IT

decision support tool allows you to interact with the evidence and your patients across the alternative options: <https://magicevidence.org/match-it/220504dist-lipid-lowering-drugs/>.

Understanding the recommendations The stratification into four cardiovascular risk groups means that, to use the recommendations, physicians need to identify their patient's risk first.

We therefore suggest, specific to various geographical regions, using some reliable risk calculators that estimate patients' cardiovascular risk based on a mix of known risk factors.

The largely weak recommendations concerning the addition of ezetimibe or PCSK9 inhibitors reflect what the panel considered to be a close balance between small reductions in stroke and myocardial infarctions weighed against the burdens and limited harms.

Because of the anticipated large variability of patients' values and preferences, well informed choices warrant shared decision making. Interactive evidence summaries and decision aids linked to the recommendations can facilitate such shared decisions. The strong

recommendations against adding another drug in people at low cardiovascular risk reflect what the panel considered to be a burden without important benefits. The strong

recommendation for adding either ezetimibe or PCSK9 inhibitors in people at high and very high cardiovascular risk reflect a clear benefit.

The panel recognised the key uncertainty in the evidence concerning patient values and preferences, namely that what most people consider important reductions in cardiovascular risks, weighed against burdens and harms, remains unclear. Finally, availability and costs will influence decisions when healthcare systems, clinicians, or people consider adding ezetimibe or PCSK9 inhibitors.

Introduction

Prevention of cardiovascular events by managing modifiable risk factors including elevated low-density lipoprotein (LDL) cholesterol represents an essential, cost effective approach to reduce the global cardiovascular disease burden.¹ Anti-protein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (PCSK9 inhibitors) and ezetimibe are newer effective lipid-lowering drugs increasingly given to patients at high cardiovascular risk to meet specific LDL cholesterol targets.

In addition to lifestyle interventions, statins are now the primary treatment to reduce numbers of cardiovascular events in people at increased risk.² Current guidelines for treating patients at high cardiovascular risk generally recommend the maximally tolerated dose of statins and other possible drugs to meet absolute levels or relative reduction of LDL cholesterol or non-HDL cholesterol (box 1). But the newer lipid-lowering drugs, particularly PCSK9 inhibitors, are expensive. Moreover, PCSK9 inhibitors are provided via subcutaneous injections which can be inconvenient. Guidelines, however, offer differing LDL cholesterol treatment targets, leaving clinicians unclear how to choose the newer expensive lipid-lowering drugs. Furthermore, concerns regarding too much medicine or overtreatment highlight the need for trustworthy guidelines that balance absolute benefits and harms to determine, for patients and society, the advisability of adding other lipid-lowering drugs to statins.¹⁰

Box Start

Box 1. Major guideline recommendations for lipid-lowering agents (PCSK9 inhibitors and ezetimibe) in adults at high or very high cardiovascular risk

European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) 2019³

- If the LDL goals—from 55 mg/dL (1.4 mmol/L) for very high risk patients to 116 mg/L (3.0 mmol/L) for low risk—are not achieved with the maximum tolerated dose of statin, combination with ezetimibe is recommended
- For very high risk patients who do not achieve their goal on a maximum tolerated dose of statin and ezetimibe, a combination with a PCSK9 inhibitor is recommended

Secondary prevention: class of recommendation I, level of evidence A

Primary prevention: class of recommendation IIb, level of evidence C

American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines updated 2019⁴

- In patients with very high cardiovascular risk, it is reasonable to add ezetimibe to maximally tolerated statin therapy when LDL cholesterol level remains ≥ 70 mg/dL (1.8 mmol/L)
- If the LDL cholesterol level on maximally tolerated statin and ezetimibe therapy remains ≥ 100 mg/dL (2.6 mmol/L), adding a PCSK9 inhibitor is reasonable
- For patients with severe primary hypercholesterolemia, the recommendations are similar, but with different LDL cholesterol targets

Class of recommendation I to IIa, level of evidence A to B-NR

Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult 2021⁵

- For all secondary prevention patients with cardiovascular diseases in whom LDL cholesterol remains ≥ 70 mg/dL (1.8 mmol/L) on maximally tolerated statin dose, intensification of lipid-lowering therapy with ezetimibe and/or PCSK9 inhibitor therapy is recommended
- If ezetimibe is used initially and LDL remains ≥ 70 mg/dL (1.8 mmol/L), PCSK9 inhibitor therapy is recommended

Strong recommendation, high quality evidence

National Institute for Health and Care Excellence (NICE) 2019⁶

- Among high risk patients with primary hypercholesterolaemia and mixed dyslipidaemia who are intolerant to statins or who fail to meet target LDL cholesterol levels (135 mg/dL (3.5 mmol/L) for very high cardiovascular risk), despite statin (and ezetimibe) therapy, use of a PCSK9 inhibitor (evolocumab or alirocumab) is approved

Unclear strength of recommendation, unclear quality of evidence

NHS England Lipids Management Pathway 2021⁷

- For primary prevention, if the maximum tolerated dose of statin does not achieve non-HDL cholesterol reduction over 40% of baseline value after 3 months consider adding ezetimibe
- For adults with a very high risk of cardiovascular risk, or if therapy is not tolerated, or LDL cholesterol remains high after adding ezetimibe and statins, consider adding PCSK9 inhibitors

Unclear strength of recommendation, unclear quality of evidence

Kaiser Permanente National Cholesterol and Cardiovascular Risk Clinician Guide 2018⁸

- For individuals with clinical atherosclerotic cardiovascular diseases and with persistently elevated blood lipids (such as LDL 130 mg/dL (3.4 mmol/L)) despite taking the maximum tolerated oral lipid-lowering therapy (statin, ezetimibe, \pm bile acid sequestrant), consider discussing adding a PCSK9 inhibitor with a lipid specialist

Unclear strength of recommendation, unclear quality of evidence

SIGN: Risk estimation and the prevention of cardiovascular disease 2017⁹

- PCSK9 inhibitors should be considered in patients at high risk of vascular events with cholesterol levels remaining above target levels (135 mg/dL (3.5 mmol/L) for secondary prevention population) despite other tolerated lipid-lowering therapy

Unclear strength of recommendation, unclear quality of evidence

Box End

The guideline panel made recommendations for adults who are receiving high doses of or are intolerant to statins with LDL cholesterol levels over 70 mg/dL (1.8 mmol/L) and considering newer lipid-lowering drugs to reduce cardiovascular risk. These recommendations address adults with and those without established cardiovascular disease (that is, primary and secondary prevention populations). The panel included PCSK9 inhibitors, ezetimibe, and a combination of both as add-on therapy to statins. This guideline differs from others in that, after specifying a minimal LDL cholesterol level below which further lipid lowering is not appropriate, recommendations are based exclusively on the absolute benefits of these drugs on cardiovascular outcomes rather than meeting targets for LDL cholesterol level.

Although systematic reviews of randomised trials show similar relative risk reductions in cardiovascular events for PCSK9 inhibitors or ezetimibe,^{11 12} the absolute benefits of these drugs depend on cardiovascular risk in individual patients. Their comparative effectiveness—with absolute benefits carefully weighed against burdens and harms—should therefore inform clinicians and their patients whether and when they should consider adding ezetimibe or a PCSK9 inhibitor to reduce cardiovascular risk. Given the complexity of multiple available treatment options, we used the following question order, thought to be representative of decisions patients and their clinicians will face:

- First, should patients add another lipid-lowering agent to current therapy?
- Second, if patients choose to add another drug, which drug should they choose (ezetimibe or a PCSK9 inhibitor)?
- Third, for those who have chosen to add one of these two drugs, should they further add the other lipid-lowering drug?

The infographic provides an overview of the risk-stratified recommendations, with evidence summaries of the benefits and harms of ezetimibe and PCSK9 inhibitors, as well as other key issues, including the burden of treatment. The MATCH-IT tool provides an interactive view of the alternative treatment options and outcomes and is also designed for shared decision making with patients (<https://magicevidence.org/match-it/220504dist-lipid-lowering-drugs/>).

Box 2 shows all evidence linked in this Rapid Recommendation package. Any new evidence that emerges after the initial publication of these recommendations will be listed in table 3 at the end of this article.

Box Start**Box 2. Linked resources in this *BMJ* Rapid Recommendations cluster**

- Hao Q, Aertgeerts B, Guyatt G, et al. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations. *BMJ* 2022;377:e069066, doi:10.1136/bmj-2021-069066
 - Summary of the results from the Rapid Recommendation process
- Khan SU, Yedlapati SH, Lone AN, et al. Anti-PCSK9 agents and ezetimibe for cardiovascular risk reduction: a systematic review and network meta-analysis. *BMJ* 2022;377:e069116, doi:10.1136/bmj-2021-069116
 - Review and network meta-analysis of all available randomised trials that assessed effects of PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction
- Harm reviews
 - Wang Y, Zhan S, Du H, et al. Safety of ezetimibe in lipid-lowering treatment: systematic review and meta-analysis of randomised controlled trials and cohort studies. *BMJ MED* 2022;1, doi:10.1136/bmjmed-2022-000134
 - Li J, Du H, Wang Y, et al. Safety of proprotein convertase subtilisin/kexin 9 inhibitors: a systematic review and meta-analysis. *Heart* 2022; doi:10.1136/heartjnl-2021-320556
- MAGICApp (<https://app.magicapp.org/#/guideline/jz7rXL>).
 - Expanded version of results with multi-layered recommendations, evidence summaries and decision aids for use on all devices

Box End

Current practice

Clinical practice guidelines differ in their recommendations. **Box 1** shows recommendations for adults at high or very high cardiovascular risk who have not achieved target LDL cholesterol levels despite the maximum tolerated dose of statin. Guidelines suggest different LDL targets, and only a minority provide clear and actionable recommendations with a defined strength; instead, several use wording such as “adding a PCSK9 inhibitor is reasonable”⁴ or “consider discussing adding PCSK9 inhibitor with a lipid specialist.”⁸ Examples of varying thresholds include the European Society of Cardiology (ESC) guidelines offering an aggressive LDL cholesterol target of 55 mg/dL (1.4 mmol/L) for patients with very high cardiovascular risk, while the American College of Cardiology/American Heart Association (AHA/ACC) guidelines set a less aggressive LDL cholesterol target of 70 mg/dL (1.8 mmol/L).^{3,4} To achieve these goals in very high risk patients with statins alone is almost impossible, so physicians are increasingly considering

other lipid-lowering drugs solely to achieve LDL cholesterol treatment goals rather than for important reduction of absolute cardiovascular risk.

Box Start

How this recommendations was created

The guideline panel

Our international panel included three patient partners (including those using and those intolerant to statins), cardiologists, general practitioners, general internists, methodologists, endocrinologists, and one geriatrician. No panel member reported financial conflicts of interest. Intellectual and professional conflicts were minimised and managed (see appendix 1 on bmj.com for details of panel members and their competing interests). The panel met online to discuss the scope of the recommendations and the patient-important outcomes that they considered most important.

What research did the guideline panel propose and review?

In addition to the primary role of lifestyle interventions, statins are now the primary treatment to reduce cardiovascular events. The panel decided that patients and clinicians should consider new lipid-lowering drugs (either a PCSK9 inhibitor or ezetimibe) after statins. The panel proposed a systematic review and network meta-analysis of randomised controlled trials on the comparative effectiveness of PCSK9 inhibitors or ezetimibe versus no PCSK9 inhibitors or ezetimibe on cardiovascular benefits.¹³ Only trials following patients for ≥ 6 months and including ≥ 500 patients were included. The panel also proposed two systematic reviews with pairwise meta-analysis of randomised controlled trials to inform adverse outcomes of adding PCSK9 inhibitors or ezetimibe to current lipid-lowering interventions.^{14 15}

What outcomes did the guideline panel consider important?

The panel considered all-cause mortality, cardiovascular mortality, non-fatal stroke, and non-fatal myocardial infarction over five years to be the critical outcomes; most eligible trials followed patients for less than 3 years. The panel considered burden of treatment to be a factor of key importance for patients.²⁹ The panel selected known adverse effects including injection site reactions leading to discontinuation, myalgia or muscular pain, and new-onset diabetes as important adverse outcomes.

Values and preferences

The panel conducted a preliminary search for patients' values and preferences regarding lipid-lowering drugs but did not find any direct research evidence to inform their judgments. Panel members completed a survey eliciting their views on the benefits that patients would consider important. The panel's judgments on patients' values and preferences showed large variability, likely reflecting varying individual patient thresholds. The panel chose the medians of the survey results for each outcome as the best estimate of the minimal important difference (MID): a reduction of 8 per 1000 for mortality, 10 per 1000 for non-fatal stroke, and 12 per 1000 for non-fatal myocardial infarction over 5 years. We used the MID to rate the imprecision of the results, and the panel considered these thresholds when discussing the final recommendations.

Risk stratification

The panel defined groups of patients at varying risk of cardiovascular events. Box 3 outlines how the panel defined risk categories. For primary prevention, the panel used the risk prediction model and calculator (PREDICT),¹⁸ defining adults to be at low, intermediate, and high risk for cardiovascular events over 5 years. For secondary prevention, all patients are defined as very high risk.

How did the guideline panel formulate the recommendations?

The panel met by videoconferences to discuss the evidence and to formulate recommendations. The panel followed the *BMJ* Rapid Recommendations procedures for creating a trustworthy recommendation, using GRADE³⁰ and MAGICapp

(www.magicapp.org) to critically appraise the evidence and create recommendations. Since this is an international guideline, the panel took an individual patient perspective, rather than a societal, public health, or health payer perspective, which largely vary among countries.

The panel focused on cardiovascular risk and absolute benefits weighed against harms and burdens or practical issues. With an individual patient perspective, what patients would find to be important cardiovascular benefits is key and hinges on their values and preferences.

In moving from evidence to recommendations, the panel reviewed evidence summaries for multiple and pairwise comparisons, considered the certainty (quality) of the evidence for each important outcome; the balance of benefits and harms of adding a PCSK9 inhibitor, ezetimibe, and possible combinations; expected variations in patients' values and preferences (informed by the survey); and the burden of treatment in the form of practical issues. The panel did not directly consider the cost of medications but recognised that cost is important from a health systems perspective and that clinicians and patients may have to deal with cost issues. The co-chairs, aiming to reach consensus, facilitated discussions and, when needed, conducted preliminary votes. Following GRADE guidance, recommendations can be strong or weak (conditional), and for or against a specific course of action.³¹ The panel succeeded in achieving consensus on all recommendations.

Box End

The evidence

Benefits of PCSK9 inhibitors and ezetimibe

The systematic review with network meta-analysis included 14 RCTs (93% were industry funded) including 83 660 individuals with or without established cardiovascular diseases.

Table 1 shows the characteristics of patients and studies, also available in the systematic review.¹³

Table 1. Characteristics of eligible studies and participants

Characteristics	Comparison		
	PCSK9 inhibitors v control	Ezetimibe v control	PCSK9 inhibitors v ezetimibe
Trials			
No of trials	10	3	1
Median (range) sample size	1590 (517 to 27 564)	2759 (1721 to 3769)	720
Median follow-up (years)	1.5	4.1	0.9
Participants			
Median or mean (range) age (years)	60.3 (56 to 66.1)	73 (65.5 to 80.6)	61.5
Median or mean (range) percentage female	35 (25 to 49)	49 (24 to 74)	26
Mean (range) baseline LDL cholesterol	92 to 128 mg/dL (2.4 to 3.3 mmol/L)	93.8 to 161 mg/dL (2.4 to 4.2 mmol/L)	106 mg/dL (2.7 mmol/L)

PCSK9 inhibitors or ezetimibe have no impact on all-cause mortality or cardiovascular mortality; this is true for all risk groups (moderate to high certainty evidence). Both PCSK9 inhibitors and ezetimibe can reduce non-fatal myocardial infarctions and stroke (moderate to high certainty evidence). PCSK9 inhibitors may have similar effects to ezetimibe on reducing non-fatal myocardial infarction or stroke (low certainty evidence). Further adding a PCSK9

inhibitor may reduce non-fatal myocardial infarction or stroke among those at very high risk (low certainty evidence).

Although we planned to conduct subgroup analyses according to certain variables—primary versus secondary prevention, follow-up duration (<1 year *versus* ≥1 year), low or high risk of bias, presence or absence of familial hypercholesterolemia—limited data in the current evidence restricted our ability to do so.

Available evidence included insufficient direct comparisons on the risk of major adverse cardiovascular event to inform the choice between PCSK9 inhibitors versus ezetimibe and the addition of one drug versus the other, therefore these recommendations were informed almost exclusively by indirect evidence. The review team did not find incoherence in direct and indirect comparisons of PCSK9 inhibitors with ezetimibe. Moreover, most eligible trials enrolled patients with high or very high cardiovascular risk, a further source of indirectness regarding people at low or moderate risk. Most of the RCTs examined the effectiveness of PCSK9 inhibitors with less than three years' follow-up, so recommendations beyond that point carry this final source of indirectness.

Harms of ezetimibe and PCSK9 inhibitors

A systematic review of potential harms from ezetimibe (47 randomised trials, 28 244 participants) with 36 weeks' median follow-up duration found moderate to high certainty evidence for no increase in any adverse events leading to discontinuation, cancer, fracture, neurocognitive events, or new-onset diabetes.¹⁴

Another systematic review of potential harms from PCSK9 inhibitors (32 trials of 65 861 participants) with 52 weeks median follow-up duration found high certainty evidence for an increase in injection-site reactions leading to discontinuation (15 per 1000 over five years). PCSK9 inhibitors were not associated with any other adverse events leading to discontinuation (low certainty), myalgia or muscular pain leading to discontinuation (moderate certainty), neurocognitive events (high certainty), or new-onset diabetes (high certainty).¹⁵

Absolute effects on benefits and harms

While harms and burdens from adding a PCSK9 inhibitor or ezetimibe are similar across different risk groups, the absolute magnitude of benefits from adding these drugs is highly dependent on individual baseline risk (see infographic) and the MATCH-IT tool, (<https://magicevidence.org/match-it/220504dist-lipid-lowering-drugs/>). The addition of

ezetimibe or a PCSK9 inhibitor to current therapy generally results in fairly similar absolute benefits and absence of serious adverse events.

Values and preference

In the absence of empirical evidence to guide decisions on what constituted important benefits to patients, the panel used inferred values and preferences documented in a survey of the panel (see “How this recommendation was created”). Using the identified thresholds for important benefit from this survey (such as 10 fewer strokes per 1000 patients treated for 5 years), the panel perceived PCSK9 inhibitors and ezetimibe both would provide important benefits for adults in the high and very high risk group, but would be of little benefit for adults in the low risk group. Having prescribed either drug in addition to current therapy, adding the second drug would provide small but important benefits for adults at high and very high risk, trivial benefits for adults with moderate risk, and little or no benefit for adults with low risk.

Understanding the recommendations

Recommendations

The guideline panel provided mostly weak recommendations as follows:

For adults taking high dose statins, with LDL cholesterol >70 mg/dL (1.8 mmol/L)

- Low risk (<5% five year risk of major adverse cardiovascular event (MACE)): We recommend not adding a second lipid-lowering drug (strong recommendation)
- Moderate risk (5-15% five year risk of MACE): We suggest not adding a second lipid-lowering drug; but for those who are considering adding a second lipid-lowering drug, we suggest adding ezetimibe first (weak recommendation); we recommend not adding a PCSK9 inhibitor to ezetimibe (strong recommendation)
- High risk (15-20% five year risk of MACE): We suggest adding a second lipid-lowering drug, preferably ezetimibe first; we suggest not adding a PCSK9 inhibitor to ezetimibe (weak recommendation)
- Very high risk (>20% five year risk of MACE): We suggest adding a second lipid-lowering drug, preferably ezetimibe first; we suggest adding a PCSK9 inhibitor to ezetimibe (weak recommendation).

For adults intolerant to statins with LDL cholesterol >70 mg/dL (1.8 mmol/L)

- Low risk (<5% five year risk of MACE): We recommend not using a lipid-lowering drug (strong recommendation)
- Moderate risk (5-15% five year risk of MACE): We suggest not using a lipid-lowering drug; but for those who are considering using a lipid-lowering drug, we suggest adding ezetimibe first (weak recommendation); we recommend not adding a PCSK9 inhibitor to ezetimibe (strong recommendation)
- **High risk (15-20% five year risk of MACE) and very high risk (>20% five year risk of MACE): We recommend using a lipid-lowering drug (strong recommendation), preferably ezetimibe first; we suggest adding a PCSK9 inhibitor to ezetimibe (weak recommendation). To whom do they apply?**

The recommendations apply to adults with LDL cholesterol >70 mg/dL (1.8 mmol/L) considering further reduction in risk of CV events who are already taking statins or are intolerant to statins. Please note that people who previously reported severe muscle symptoms when taking statins (may be labelled as intolerant to statins) should first consider restarting statins at a low dose to reduce their cardiovascular risk, as many could have a nocebo effect or combined effect.^{16 17}

This guideline represents a shift from the traditional focus on lipid level goals to a focus on reducing an individual's overall cardiovascular risk. Clinicians need to identify patients' individual cardiovascular risks to apply these risk-stratified recommendations. The use of these recommendations therefore warrants explicit judgments of individual baseline cardiovascular risk, using credible risk calculators applicable to specific geographic regions. Most risk prediction tools use a cardiovascular risk over a period of 10 years,¹ but this is not consistent with many trials on interventions for cardiovascular risk, which rarely extend beyond five years. The panel chose the most widely applicable calculator (PREDICT) to estimate patients' risk, of mortality, non-fatal myocardial infarction, and non-fatal stroke over five years, in part because PREDICT provides risk estimates for both primary and secondary prevention populations (appendix 2). **Box 3** presents our approach to risk stratification, with key characteristics to consider displayed in the infographic.

Box Start

Box 3 Risk stratification approach and baseline risk estimation for the guideline

The panel estimated baseline risks for individual outcomes (mortality, non-fatal myocardial infarction, and non-fatal stroke) over a five year timeframe. We used medians of the risk within each risk category from the PREDICT cohort¹⁸ as the baseline risk estimates. The PREDICT cohort includes five ethnic populations (European, Maori, Pacific, Indian, Chinese or other Asian) and 11 risk attributes.

Primary prevention population (patients typically seen in primary care)

- Low risk—Patients with 1-2 cardiovascular risk factors (<5% five year risk of major adverse cardiovascular event (MACE), median 2%)
- Moderate risk—Patients with 3-4 cardiovascular risk factors (5-15% five year risk of MACE, median 7%)
- High risk—Patients with ≥5 cardiovascular risk factors or hereditary or familial lipid disorder (15-20% five year risk of MACE, median 18%).

Secondary prevention population (patients typically seen in specialist health care)

- Very high risk—Patients with established cardiovascular diseases (>20% five year risk of MACE, median 24%).

Assumptions

Statins reduce cardiovascular risk. We used the relative risk reductions from a previously published systematic review for adding statins to no drug treatment (without statins).¹⁹ MACE is a composite outcome, but the panel was interested in the effects on individual components. To unravel MACE, we used a set of assumptions supported by previous

studies reporting the general distributions for different events.^{20 21} Non-fatal myocardial infarction and stroke will occur nine times more often than cardiovascular deaths. Non-fatal myocardial infarction will occur 1.3 more often than non-fatal stroke, and all-cause mortality will occur 1.5 times more often than cardiovascular mortality. This method did not, however, take account of the proportions of the individual outcomes in MACE being age and sex dependent. We chose fixed proportions to avoid unmanageable complexity (see appendix 2 on bmj.com).

Box End

Values and preferences variability

The panel recognised that values and preferences probably vary widely across patients. Our recommendations reflect a belief that most patients value a modest reduction in myocardial infarction or stroke over five years, including absolute reductions in the order of 10 per 1000. However, some patients may value smaller reductions in these major events. The main burden of treatment with PCSK9 inhibitors is injections and risk of local skin reactions. The panel’s recommendations are based on the members’ inference that patients consider the burden of regular medication, including periodic injections, would be outweighed by an important reduction in major events.

The panel made one strong recommendation based on low quality evidence; for adults already receiving high dose statins at moderate cardiovascular risk, we recommend against adding a PCSK9 inhibitor to ezetimibe and statins. For this recommendation, the panel placed a high priority on avoiding the burden of injections and minimising the use of polypharmacy and the possibility of drug-drug interactions²² when there are no clear benefits on major adverse cardiovascular events.

Shared decision making, including practical issues

Shared decision making is particularly important when recommendations are weak and values and preferences are likely to vary substantially. When adding PCSK9 inhibitors or ezetimibe, the previous lipid-lowering drug (maximally tolerated statins) would remain unchanged. Many people may prefer oral medicines to injectable drugs.²³ Implementing injection medications may introduce various barriers and need effective communication with patients.^{24 25} **Table 2** shows the practical issues regarding adding a PCSK9 inhibitor or ezetimibe or statins alone.

Table 2. Practical issues about use of PCSK9 inhibitors and ezetimibe in adults

	PCSK9 inhibitors	Ezetimibe	Statins
Medication routine	Administered every 2 weeks or monthly by subcutaneous injection (inclisiran can be given every 6 months)	Tablets taken once daily at any time of day. Ezetimibe-statin combination pills are available	Tablets taken once daily

Test and visit	Regular blood samples or visits after starting a new medication to monitor adherence and potential harms are encouraged		
Recovery and adaptation	Most people need to take these medications for the rest of their lives.		
Adverse effects, interactions, and antidote	Injection site reactions are usually mild, including pain, erythema or allergic effects. Muscle toxicity or hepatic dysfunction seem uncommon. The overall incidence of side effects is similar to placebo. Long term (>3 years) safety issues need further investigation	Adverse reactions are mild and transient, including gastrointestinal events, myalgia or muscular pain, hepatic dysfunction, headache, and fatigue. The overall incidence of side effects is similar to placebo	The commonest adverse effects are muscle related ($\leq 72\%$ of all adverse events) and hepatic dysfunction. For a specific person experiencing muscle related discomfort, clinicians should not attribute this to statin or nocebo effect without careful case-by-case investigation ²⁶
Physical wellbeing	All drugs have no or little effect on body weight.		
Emotional wellbeing	Emotional stress can occur from starting or adding new injection medication and be related to side effects, especially for long term safety issues.	Emotional stress can occur from adding new oral medication related to side effects	
Pregnancy and nursing	All lipid-lowering drugs should be avoided during pregnancy and nursing or in women who may become pregnant. Lifestyle interventions can be considered during pregnancy and nursing as general management for dyslipidaemias		
Costs and access	Costs vary between specific agents and depend on health insurance and policy. Even though the cost will hugely affect the individual or society's decision, we put the cost aside when we make our recommendations. PCSK9 inhibitors are the most expensive drugs among the drugs and not easy to access	Ezetimibe is more expensive than statins but much cheaper than PCSK9 inhibitors and easy to access	Statins are generally inexpensive and easy to access
Food and drinks	A diet to maintain a healthy weight (such as Mediterranean diet) is advised as general management for patients with dyslipidaemias		
Storage and transportation before use	PCSK9 inhibitors should be stored and transported at 2-8°C and avoid sunshine and freezing	Drugs should be stored in a dry environment below 30°C and avoid sunshine	
Exercise and activities	Exercise and activities are advised as a general management for patients with dyslipidaemias		
Travel time and driving	Patients may need special equipment to transport their drugs and injection equipment when undertaking long travel	No influence	

Costs and availability

Both ezetimibe and statins are generically available worldwide. Ezetimibe is more expensive than statins but much cheaper than PCSK9 inhibitors. PCSK9 inhibitors are delivered by injection and require special equipment when using or travelling. Two PCSK9

inhibitors (alirocumab, evolocumab) have been approved and are available in Europe, US, and Canada, with inclisiran so far approved only in Europe. Because of cost, storage and transportation requirements, and local health policy, they are unavailable in many other countries or areas, especially middle or low income countries. Our recommendations do not consider medication costs. However, the panel recognises that, for patients who have to bear the costs of medication, the cost may prove decisive.

Costs of PCSK9 inhibitors are potentially prohibitive, and a key factor in a healthcare systems perspective. A related cost-effectiveness analysis reported variable results: some, but not all, studies suggest that the addition of evolocumab or alicumab to maximally tolerated statin therapy, with or without ezetimibe, with current pricing, may meet accepted cost-effectiveness thresholds in the US among patients at very high risk of atherosclerotic cardiovascular diseases.^{27 28}

Although the guideline panel, in making recommendations from the perspective of patients, did not directly consider the cost of medication, our recommendations are in line with the preference with the cost-effectiveness concerns and drug availability, favouring ezetimibe over PCSK9 inhibitors in people needing another lipid-lowering drug. Clinicians and patients need to consider the cost based on the local scenario.

Uncertainty

There are several limitations in the evidence underlying this guideline, resulting in uncertainties and key research questions. First, there is almost no direct evidence on major adverse cardiovascular event to inform comparisons between PCSK9 inhibitors and ezetimibe, and the addition of one of these drugs to the other. There is also little direct evidence in moderate or low risk individuals and long term effects (over 3 years) or safety issues for adding PCSK9 inhibitors. These limitations in the evidence explain in part the panel's reluctance to recommend adding the two drugs to patients at low or moderate cardiovascular risk.

Second, we know little about the values and preferences of adults considering lipid-lowering drugs: our survey leaves great uncertainty about the true distribution of values and preferences and highlights the need for further research. For example, formal qualitative or quantitative studies could provide insight into patients' values and preferences, and particularly into the minimal important difference on important cardiovascular outcomes in the context of different cultures and health systems.

Third, the long term (over three years) side effects of adding a PCSK9 inhibitor are unclear. Long term drug surveillance and monitoring of adverse reactions will provide further evidence on this issue. Furthermore, the PREDICT tool was developed based on cohorts from New Zealand, and thus other populations may have somewhat different levels or determinants of risk than PREDICT.

Tips on calculating cardiovascular risk

We suggest that patients and clinicians use the most reliable risk calculator that suits the local population to estimate patients' cardiovascular risk. **Box 4** lists validated risk calculators in the published literature. If such calculators are unavailable or unfeasible, we suggest the following strategy to identify individual cardiovascular risk: for primary prevention, clinicians need to calculate patients' cardiovascular risk based on risk factors of cardiovascular disease, including but not limited to older age (>50 years old), male, tobacco use, diabetes, family history of cardiovascular disease, high blood pressure, elevated total cholesterol, and reduced high-density lipoprotein-cholesterol. For secondary prevention populations, clinicians can identify patients with established cardiovascular disease.

Baseline cardiovascular risk may vary across countries and ethnicities. Although we suggest using reliable risk calculators validated in specific geographic settings, these tools cannot take account of all cardiovascular risk factors, and clinicians therefore need to use such tools with caution, supplemented by their clinical expertise. New emerging biomarkers such as lipoprotein(a) and coronary artery calcium score might be helpful for further risk stratification.

Box Start

Box 4. Validated risk calculators in literature for reference.

- Framingham Risk Score-Cardiovascular Disease: <https://framinghamheartstudy.org/fhs-risk-functions/>
- American College of Cardiology/American Heart Association (ACC/AHA) Pooled Cohort Equations (PCE): <https://tools.acc.org/ascvd-risk-estimator-plus/#!/calculate/estimate/>
- SCORE2 (Systematic Coronary Risk Estimation): <https://www.escardio.org/Education/Practice-Tools/CVD-prevention-toolbox/SCORE-Risk-Charts>
- QRISK: <https://www.qrisk.org/>
- China-PAR: <https://www.cvdrisk.com.cn/ASCVD/Eval>
- PREDICT: <https://cvdrisk.mohio.co.nz/>
- Australian absolute cardiovascular disease risk calculator: <https://www.cvdcheck.org.au/calculator>
- WHO risk charts: <https://www.who.int/news/item/02-09-2019-who-updates-cardiovascular-risk-charts>

Note: Most risk calculators calculate cardiovascular risk over 10 years, whereas our recommendations are based on five year cardiovascular risk (appendix 2). Clinicians can estimate five year risk by dividing 10 year calculator estimates in half, if we assume that the risks are distributed evenly. These tools may overestimate risk as they were developed when baseline cardiovascular risks were higher than is currently the case.

Box End

Updates to this article

Table 3 shows evidence that has emerged since the publication of this article. As new evidence is published, a group will assess the new evidence and make a judgment on the desirability of altering the recommendation.

Table 3. New evidence which has emerged after the initial publication of this article

Date	New evidence	Citation	Findings	Implications for recommendation
------	--------------	----------	----------	---------------------------------

There are currently no updates to the article. The MAGIC workgroup will monitor related evidence. The steering group will start updating the recommendations when potential practice-changing evidence emerges.

Box Start

Education into practice

- How will you identify patients who might require a change in their lipid medication regime based on these recommendations?
- How will you help individuals to make a choice about PCSK9 inhibitors or ezetimibe after they reach the maximum dose of statins or are intolerant to statins?
- What cardiovascular risk calculator is most appropriate to use locally for your population in order to implement these recommendations?

Box End

Box Start

How patients were involved in the creation of this article

Three patients who have taken lipid-lowering drugs (including one patient with intolerance to statins) were full panel members. Before the formal discussion with the whole panel, our patient partnership liaisons (Geertruida Bekkering and Lyubov Lytvyn) hosted small meetings with patient partners only to discuss the guideline process and the evidence. During the survey and the meeting, the steering group and meeting chairs emphasised patient partners' voices for consideration.

The three patient partners helped the panel identify important outcomes and rated outcomes, led the discussion on values and preferences, and participated in the teleconferences and email discussions on the evidence and recommendation. They also contributed to the identification of practical issues related to the decision of choosing lipid-lowering drugs and met all authorship criteria for the present guideline. We thank them for their great contribution.

Box End

Web Extra Extra material supplied by the author

[Appendix 1: Full list of authors and summary of their competing interests](#)

file: haoq069066.w1

[Appendix 2: Rationale for choice of risk stratification](#)

file: haoq069066.w2

This *BMJ* Rapid Recommendations article is one of a series that provides clinicians with trustworthy recommendations for potentially practice changing evidence. *BMJ* Rapid Recommendations represent a collaborative effort between the MAGIC group

(www.magicvidence.org) and *The BMJ*. A summary is offered here, and the full version including decision aids is on the MAGICapp (www.magicapp.org), for all devices in multilayered formats. Those reading and using these recommendations should consider individual patient circumstances and their values and preferences and may want to use consultation decision aids in MAGICapp to facilitate shared decision making with patients. We encourage adaptation of recommendations to allow contextualisation of recommendations and to reduce duplication of work. Those considering use or adaptation of content may go to MAGICapp to link or extract its content or contact *The BMJ* for permission to reuse content in this article.

We thank panel member Hans Van Brabandt for his contribution in identifying critical outcomes and finalising clinical questions for the guideline. We learnt of his passing with great sadness.

Competing interests: All authors have completed the *BMJ* Rapid Recommendations interest disclosure form and a detailed, contextualised description of all disclosures is reported in web appendix 1. As with all *BMJ* Rapid Recommendations, the executive team and *The BMJ* judged that no panel member had any financial conflict of interest. Professional and academic interests were minimised as much as possible, while maintaining necessary expertise on the panel to make fully informed decisions.

Disclaimer: Participation in the panel and authorship of this manuscript does not constitute organisational endorsement of the recommendations.

Funding This guideline was funded by 1.3·5 project for disciplines of excellence—Clinical Research Incubation Project, West China Hospital, Sichuan University (Nos. 19HXFH011, ZYGD18022 and 2020HXF011). Nicolas Rodondi's work is partly funded by a grant from the Swiss National Scientific Foundation (SNSF 33IC30_193051/1) about assessing the role of statins in multimorbid older adults without cardiovascular disease.

Transparency: N Delvaux and S Li affirm that the manuscript is an honest, accurate, and transparent account of the recommendation being reported; that no important aspects of the recommendation have been omitted; and that any discrepancies from the recommendation as planned have been explained.

Copyright statement The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be published in *BMJ* and any other BMJ PGL products and sublicences such use and exploit all subsidiary rights, as set out in our licence (<https://authors.bmj.com/policies/#copyright>).

1. El Fakiri F, Bruijnzeels MA, Hoes AW. Prevention of cardiovascular diseases: focus on modifiable cardiovascular risk. *Heart* 2006;92:741-5. doi: 10.1136/hrt.2005.068114 pmid: 16251231
2. Rached F, Santos RD. The role of statins in current guidelines. *Curr Atheroscler Rep* 2020;22:50. doi: 10.1007/s11883-020-00861-9 pmid: 32770357
3. Mach F, Baigent C, Catapano AL, et al. ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *Eur Heart J* 2020;41:111-88. doi: 10.1093/eurheartj/ehz455 pmid: 31504418
4. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation* 2019;139:e1082-143. pmid: 30586774
5. Pearson GJ, Thanassoulis G, Anderson TJ, et al. 2021 Canadian Cardiovascular Society Guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. *Can J Cardiol* 2021;37:1129-50. doi: 10.1016/j.cjca.2021.03.016 pmid: 33781847
6. National Institute for Health and Care Excellence. Innovative medicines optimisation clinic for PCSK9 inhibitors & statin intolerance. 2019. <https://www.nice.org.uk/sharedlearning/innovativemedicines-optimisation-clinic-for-pcsk9-inhibitors-statin-intolerance>.
7. South East London (SEL) Integrated Care System. Lipid management: medicines optimisation pathways. 2021. https://selondonccg.nhs.uk/wp-content/uploads/dlm_uploads/2021/09/Lipidsmanagement-pathways-for-South-East-London-FINAL-September-2021.pdf.
8. Kaiser Permanente National. Clinical practice guidelines. Cholesterol and cardiovascular risk: clinician guide. 2018. <https://kpcmi.org/files/cholesterol-clinician-guide.pdf>.
9. SIGN. SIGN 149. Risk estimation and the prevention of cardiovascular disease. 2017. <https://www.sign.ac.uk/assets/sign149.pdf>.
10. Byrne P, Cullinan J, Smith SM. Statins for primary prevention of cardiovascular disease. *BMJ* 2019;367:l5674. doi: 10.1136/bmj.l5674 pmid: 31619406
11. Du H, Li X, Su N, et al. Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and meta-analysis. *Heart* 2019;105:1149-59. doi: 10.1136/heartjnl-2019-314763 pmid: 30842207
12. Khan SU, Talluri S, Riaz H, et al. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes. *Eur J Prev Cardiol* 2018;25:844-53. doi: 10.1177/2047487318766612 pmid: 29569492
13. Khan SU, Yedlapati SH, Lone AN, et al. Anti-PCSK9 agents and ezetimibe for cardiovascular risk reduction: a systematic review and network meta-analysis. *BMJ* 2022;377:e069116, doi: 10.1136/bmj-2021-069116.
14. Wang Y, Zhan S, Du H, et al. Safety of ezetimibe in lipid-lowering treatment: systematic review and meta-analysis of randomised controlled trials and cohort studies. *BMJ MED* 2022;doi: 10.1136/bmjmed-2022-000134.
15. Li J, Du H, Wang Y, et al. Safety of proprotein convertase subtilisin/kexin 9 inhibitors: a systematic review and meta-analysis. *Heart* 2022; doi: 10.1136/heartjnl-2021-320556.

16. Herrett E, Williamson E, Brack K, et al. StatinWISE Trial Group. Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials. *BMJ* 2021;372:n135. doi: 10.1136/bmj.n135 pmid: 33627334
17. Howard JP, Wood FA, Finegold JA, et al. Side effect patterns in a crossover trial of statin, placebo, and no treatment. *J Am Coll Cardiol* 2021;78:1210-22. doi: 10.1016/j.jacc.2021.07.022 pmid: 34531021
18. Pylypchuk R, Wells S, Kerr A, et al. Cardiovascular disease risk prediction equations in 400 000 primary care patients in New Zealand: a derivation and validation study. *Lancet* 2018;391:1897-907. doi: 10.1016/S0140-6736(18)30664-0 pmid: 29735391
19. Khan SU, Talluri S, Riaz H, et al. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes. *Eur J Prev Cardiol* 2018;25:844-53. doi: 10.1177/2047487318766612 pmid: 29569492
20. Jørstad HT, Colkesen EB, Boekholdt SM, et al. Estimated 10-year cardiovascular mortality seriously underestimates overall cardiovascular risk. *Heart* 2016;102:63-8. doi: 10.1136/heartjnl-2015-307668 pmid: 26261158
21. Miao B, Hernandez AV, Alberts MJ, Mangiafico N, Roman YM, Coleman CI. Incidence and predictors of major adverse cardiovascular events in patients with established atherosclerotic disease or multiple risk factors. *J Am Heart Assoc* 2020;9:e014402. doi: 10.1161/JAHA.119.014402 pmid: 31937196
22. Andrews JC, Schünemann HJ, Oxman AD, et al. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength. *J Clin Epidemiol* 2013;66:726-35. doi: 10.1016/j.jclinepi.2013.02.003 pmid: 23570745
23. González-González JG, Díaz González-Colmenero A, Millán-Alanís JM, et al. Values, preferences and burden of treatment for the initiation of GLP-1 receptor agonists and SGLT-2 inhibitors in adult patients with type 2 diabetes: a systematic review. *BMJ Open* 2021;11:e049130. doi: 10.1136/bmjopen-2021-049130 pmid: 34244276
24. Khatib R, Angus N, Hansen TB, et al. Perceptions of injectable therapies with cardiovascular benefit: an ACNAP survey of healthcare professionals to explore facilitators and barriers. *Eur J Cardiovasc Nurs* 2021; doi: 10.1093/eurjcn/zvab106. pmid: 34849708
25. Lambrinou E, Kyriakou M, Lakatamitou I, et al. An integrative review on facilitators and barriers in delivering and managing injectable therapies in chronic conditions: A part of the ACNAP project 'injectable medicines among patients with cardiovascular conditions'. *Eur J Cardiovasc Nurs* 2020;19:663-80. doi: 10.1177/1474515120939007 pmid: 32672477
26. Wood FA, Howard JP, Finegold JA, et al. N-of-1 trial of a statin, placebo, or no treatment to assess side effects. *N Engl J Med* 2020;383:2182-4. doi: 10.1056/NEJMc2031173 pmid: 33196154
27. Fonarow GC, van Hout B, Villa G, Arellano J, Lindgren P. Updated cost-effectiveness analysis of evolocumab in patients with very high-risk atherosclerotic cardiovascular disease. *JAMA Cardiol* 2019;4:691-5. doi: 10.1001/jamacardio.2019.1647 pmid: 31166576
28. Kazi DS, Penko J, Coxson PG, Guzman D, Wei PC, Bibbins-Domingo K. Cost-effectiveness of alirocumab: a just-in-time analysis based on the ODYSSEY Outcomes Trial. *Ann Intern Med* 2019;170:221-9. doi: 10.7326/M18-1776 pmid: 30597485
29. Heen AF, Vandvik PO, Brandt L, et al. A framework for practical issues was developed to inform shared decision-making tools and clinical guidelines. *J Clin Epidemiol* 2021;129:104-13. doi: 10.1016/j.jclinepi.2020.10.002 pmid: 33049326

30. Siemieniuk RA, Agoritsas T, Macdonald H, Guyatt GH, Brandt L, Vandvik PO. Introduction to BMJ Rapid Recommendations. *BMJ* 2016;354:i5191. doi: 10.1136/bmj.i5191 pmid: 27680768
31. Guyatt GH, Oxman AD, Kunz R, et al GRADE Working Group. Going from evidence to recommendations. *BMJ* 2008;336:1049-51. doi: 10.1136/bmj.39493.646875.AE pmid: 8467413